Prior authorization: confirm ALL coverage criteria

Submit a prior authorization request that documents ALL policy criteria are satisfied before MSA: age ≥18 years; BMI <35 kg/m2; objective evidence of pathologic acid exposure by esophageal pH monitoring; persistent daily GERD symptoms despite ≥6 months of documented optimized medical therapy including lifestyle modification and maximum or maximally tolerated PPI therapy; and if hiatal hernia >2 cm, plan for repair prior to or at time of MSA.

• Age: individual is 18 years or older.
• BMI: less than 35 kg/m2.
• Objective pH monitoring confirming pathologic acid exposure.
• At least 6 months of documented adherence to optimized medical therapy (lifestyle + PPI).
• If hiatal hernia >2 cm, documentation that hernia will be repaired prior to or at MSA.

Prior authorization implied by required pre-op evaluation

Prior authorization is implied because providers must document a comprehensive pre-operative evaluation prior to MSA, typically including upper endoscopy, high-resolution esophageal manometry, pH testing, and an upper GI series (barium swallow).

• Endoscopy (upper endoscopy) documented.
• High-resolution esophageal manometry results included.
• Esophageal pH testing results provided.
• Upper GI series (barium swallow) included when performed.

Prior authorization: document preoperative workup and optimized therapy

Obtain and submit documentation that guideline-recommended preoperative workup was completed and that medical therapy was optimized before MSA is authorized: upper endoscopy, high-resolution manometry, and ambulatory pH monitoring per SAGES guidance and ACG/other guidelines.

• Document comprehensive preoperative evaluation per SAGES: upper endoscopy, high-resolution manometry, ambulatory pH monitoring.
• Document verification and optimization of PPI therapy as recommended by ACG (timing, adherence, and escalation to twice-daily when indicated).

Prior authorization for MSA CPT codes (43284/43285)

Request prior authorization for procedures billed with CPT 43284 (placement) or 43285 (removal) for members with GERD diagnoses (ICD-10 K21.0, K21.9); note that codes may be subject to coverage review and may not be covered under all circumstances.

• CPT 43284 — placement of sphincter augmentation device (including cruroplasty when performed).
• CPT 43285 — removal of esophageal sphincter augmentation device.
• Use ICD-10 diagnosis codes K21.0 or K21.9 as applicable.

Prior authorization contingent on product coverage

Verify product benefit coverage before submitting authorization: medical policy criteria and prior authorization requirements apply only when the member's product covers the service, and requirements are product-dependent.

• If the member's product does not cover the service, the policy criteria do not apply.
• Prior authorization requirements vary by product (commercial, Medicaid, Medicare).

Required prior medical therapy: ≥6 months documented

Document at least 6 months of prior medical therapy adherence before MSA authorization, including lifestyle modification and maximum or maximally tolerated PPI therapy.

• Evidence of lifestyle modification (e.g., weight reduction when indicated).
• Documentation of maximum or maximally tolerated PPI therapy for ≥6 months.

Optimized PPI therapy required before MSA

Show optimized PPI therapy before considering MSA: confirmed adherence, correct pre-meal dosing, supportive lifestyle measures, and trials of once-daily followed by twice-daily dosing unless a serious side effect is documented.

• Confirm PPI taken 30–60 minutes before a meal when indicated.
• Document trial of once-daily then escalation to twice-daily dosing if symptoms persist, or documentation of serious side effects if escalation not possible.

Medication optimization per guidelines before procedural therapy

Document that medication optimization was attempted per guidelines: an initial 8-week trial of once-daily PPI taken 30–60 minutes before meals with verification of timing and adherence and escalation to twice-daily dosing when indicated before labeling symptoms as refractory.

• Initial 8-week once-daily PPI trial with correct timing (30–60 minutes before a meal).
• Verification of adherence and dose timing, with consideration of twice-daily dosing prior to procedural therapy.

Consideration of prior medical management vs procedural therapy

Consider prior medical management in shared decision-making: guidelines indicate MSA may be an alternative to continued PPI therapy or fundoplication for selected patients after optimization of medical therapy.

• MSA may be chosen over continued PPI use in selected patients.
• Choice between MSA and fundoplication should be individualized based on patient factors (e.g., BMI, motility).

Required supporting documentation for prior authorization

Include objective supporting documentation with authorization: esophageal pH monitoring demonstrating pathologic acid exposure, documentation of ≥6 months adherence to optimized medical therapy (lifestyle + PPI), and, when applicable, documentation that hiatal hernia >2 cm will be repaired prior to or at MSA.

• Esophageal pH monitoring report confirming pathologic acid exposure.
• Clinical records showing ≥6 months of optimized medical therapy and adherence.
• Surgical plan or notes indicating hiatal hernia repair if hernia >2 cm.

Required pre‑operative documentation

Provide comprehensive pre‑operative documentation prior to MSA: upper endoscopy, high-resolution esophageal manometry, ambulatory pH monitoring, and upper GI series as part of the preoperative evaluation.

• Upper endoscopy report.
• High-resolution esophageal manometry results.
• Ambulatory (or other) pH monitoring report.
• Upper GI (barium) series when performed.

Preoperative evaluation and medical management documentation (SAGES/ACG)

Document preoperative evaluation and medical management per society guidance: SAGES recommends upper endoscopy, high-resolution manometry, and ambulatory pH monitoring; also include documentation of PPI trial optimization (timing, adherence, dosing escalation).

• Documentation that SAGES-recommended preoperative tests were completed.
• Records verifying PPI optimization per ACG guidance (timing and adherence).

Documentation of device labeling alignment and clinician qualifications

Ensure documentation demonstrates device use aligns with FDA labeling and that clinicians performing MSA have appropriate training and experience in foregut surgery and GERD management per NICE and SAGES recommendations.

• Reference FDA PMA labeling where applicable.
• Confirm surgeon has training/experience in foregut surgery and GERD management.

Refer to device IFU and FDA PMA in documentation

When applicable, reference the LINX device Instructions for Use (IFU) and FDA PMA documents in the record to demonstrate device-specific indications, contraindications, and labeling considerations.

• Torax Medical/LINX IFU (2023) and FDA PMA P100049 with supplements cited in records as relevant.
• Use IFU/PMA information to confirm required hiatal hernia repair guidance and other labeling points.

Contraindications/precautions — documentation to avoid denial

Absence of listed contraindications/precautions must be documented; presence of major esophageal motility disorders, LA Grade C/D esophagitis, esophageal stricture/significant anatomic abnormalities, varices, suspected/confirmed cancer, scleroderma, or allergy to device metals may preclude coverage and trigger denial.

• Document absence of major motility disorders (e.g., achalasia, distal spasm, hypercontractile esophagus, absent contractility).
• Document absence of LA Grade C or D esophagitis.
• Document absence of strictures, varices, suspected/confirmed esophageal or gastric cancer, scleroderma, or metal allergies.

Denial risk: incomplete pre‑operative evaluation

Failure to provide a comprehensive pre‑operative evaluation (endoscopy, high-resolution manometry, pH testing, upper GI series) before MSA may be grounds for denial; include these reports with authorization requests.

• Missing endoscopy, manometry, or pH testing reports increases risk of denial.
• Upper GI series should be included when part of the workup.

Clinician qualification requirement — experienced foregut surgeons

MSA should be performed by surgeons experienced in foregut surgery and GERD management; absence of appropriate surgeon experience or performance by non‑specialists may lead to unfavorable outcomes and implicit risk for denial.

• Confirm surgeon training and experience in foregut/antireflux procedures per SAGES guidance.
• Do not offer MSA in isolation without appropriate multidisciplinary evaluation.

Coverage exceptions and denial risk for codes

Be aware that codes for MSA may be designated E/I or NMN in some situations; coverage exceptions exist and codes may not be covered under all circumstances.

• Check coverage determination for E/I (experimental/investigational) or NMN (not medically necessary) indicators.
• Authorization decisions may vary by circumstance and documentation.

Contract coverage dependency — verify product benefits first

Confirm the member’s product coverage before pursuing authorization: services are contract dependent and the medical policy criteria apply only when the product covers the service.

• Verify commercial, Medicaid, or Medicare product rules before authorization.
• If product excludes the service, do not apply the medical policy criteria.